Iterum Therapeutics plc Quarterly Nonoperating Income (Expense) in USD from Q2 2017 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Iterum Therapeutics plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2017 to Q4 2024.
  • Iterum Therapeutics plc Nonoperating Income (Expense) for the quarter ending December 31, 2024 was -$2.89M, a 266% decline year-over-year.
  • Iterum Therapeutics plc Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was -$5.84M, a 160% decline year-over-year.
  • Iterum Therapeutics plc annual Nonoperating Income (Expense) for 2024 was -$5.84M, a 160% decline from 2023.
  • Iterum Therapeutics plc annual Nonoperating Income (Expense) for 2023 was $9.71M.
  • Iterum Therapeutics plc annual Nonoperating Income (Expense) for 2022 was -$13.8M, a 79.3% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 -$5.84M -$2.89M -$2.1M -266% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-07
Q3 2024 -$3.74M -$1.07M -$14M -108% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $10.3M -$990K +$244K +19.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $10.1M -$890K +$346K +28% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $9.71M -$789K -$3.73M -127% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-07
Q3 2023 $13.4M $13M +$35.6M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$22.2M -$1.23M -$2.89M -174% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$19.3M -$1.24M -$5.54M -129% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$13.8M $2.94M +$119K +4.22% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-07
Q3 2022 -$13.9M -$22.6M -$31.6M -353% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $17.7M $1.66M -$13.2M -88.9% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $31M $4.3M +$97.3M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$66.3M $2.82M +$9.34M Oct 1, 2021 Dec 31, 2021 10-K 2024-03-28
Q3 2021 -$75.7M $8.97M +$14.4M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$90.1M $14.9M +$19M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 -$109M -$93M -$89.9M -2915% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 -$19.1M -$6.52M -$6.1M -1474% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-16
Q3 2020 -$13M -$5.44M -$5.28M -3140% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$7.76M -$4.09M -$3.99M -3871% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 -$3.77M -$3.09M -$3.11M -15525% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 -$665K -$414K -$306K -283% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-28
Q3 2019 -$359K -$168K -$358K -188% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$1K -$103K +$150K +59.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$151K $20K -$126K -86.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
Q4 2018 -$25K -$108K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-12
Q3 2018 $190K -$23K -10.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$253K -$464K -220% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $146K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-14
Q3 2017 $213K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 $211K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.